UW-Madison Originated Regenerative Skin Tissue Product for Burn Wounds Performs Well in Phase III Clinical Trial

UW-Madison Originated Regenerative Skin Tissue Product for Burn Wounds Performs Well in Phase III Clinical Trial

Madison, WI-based Stratatech (part of UK-based Mallinckrodt) completed a study demonstrating burn wounds treated in the clinical trial mostly healed well and rarely required patient skin grafts in findings that will lead to an application for Food and Drug...
UCLA Investigators Lead Study of Novartis’ Ribociclib Significantly Improves Overall Survival for Aggressive Breast Cancer

UCLA Investigators Lead Study of Novartis’ Ribociclib Significantly Improves Overall Survival for Aggressive Breast Cancer

UCLA investigators helped lead a study that found by adding Novartis’ ribociclib, a targeted therapy drug, to standard hormone therapy, they can significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer....

Pin It on Pinterest